Rheumatoid Arthritis Clinical Trial
Official title:
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis
Evaluation of Health Related Quality of Life (HRQL) is of a paramount importance in
assessing the impact of rheumatoid arthritis on patients' health status, however when costs
associated with rheumatoid arthritis are also taken into account, the information provided
may lead to a more balanced view in analyzing the treatment of the disease.
In accordance with the above, the main objective this study was to evaluate the impact of
adalimumab treatment not only on patients' Health Related Quality of Life but also on the
cost of the disease management. In order to accomplish this the study has been focused on:
1. Estimating the direct and indirect cost incurred by adalimumab treatment.
2. Measuring the Health Related Quality of Life of rheumatoid arthritis patients under
adalimumab treatment.
3. Exploring the cost-utility relationship of rheumatoid arthritis patients treated with
adalimumab by combining the Health Related Quality of Life of rheumatoid arthritis
patients and direct as well as indirect costs due to RA.
More specifically, data related to patients' Health Related Quality of Life and cost
associated with rheumatoid arthritis will be recorded for one-year period, and collected at
four subsequent visits: baseline, month 3, 6 and 12. The visit before starting treatment
with adalimumab will be considered as baseline. This information was used to compare Health
Related Quality of Life and cost data before and after adalimumab initiation and therefore
identify the effect of adalimumab treatment in patients with rheumatoid arthritis.
Data concerning patients' Health Related Quality of Life as well as the cost of the disease
treatment were collected at four subsequent periods and specifically at baseline (Visit 1),
and at months 3, 6 and 12.
Moreover, at baseline patients' socioeconomic, and history of illness data as well as the
use of other prescribed medication and costs due to rheumatoid arthritis have been recorded,
in order to identify patients' health state before adalimumab treatment initiation.
Patients discontinuing therapy (drop-outs) either due to adverse events or on their own
initiative were categorized and analyzed separately, while reasons leading to
discontinuation were recorded. Adverse events were not collected in this study with the
exception of adverse events leading to withdrawal.
In order to evaluate the cost-utility of adalimumab both the cost of the disease treatment
and the Health Related Quality of Life of rheumatoid arthritis patients have been taken into
account. The process is described below:
Face-to-face interviews were conducted by the physicians/investigators in charge in all four
subsequent periods as well as before adalimumab treatment initiation. A questionnaire,
divided into the following sections, was administered: 1. Patients' Sociodemographic
Characteristics 2. Measurement of Health Related Quality of Life in Rheumatoid Arthritis
patients 3. Cost Assessment
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |